Search
Eli Lilly and Co
LLYAdd to Watchlist
1178.980USD
-12.960-1.09%
Market hours （ET）Quotes delayed by 15 min
1.11TMarket Cap
41.81P/E TTM
Forecast
Currency: USD Updated: 2026-08-06The current earnings forecast score of Eli Lilly and Co is 8.12, ranking 55 out of 156 in the Pharmaceuticals industry. The average price target is 1055.00, with a high of 1500.00 and a low of 706.04.
Analyst Rating
Based on
34
analysts
Buy
Current Rating
1245.374
Target Price
+11.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Eli Lilly and Co
LLY
34
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Merck & Co Inc
MRK
32
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Eli Lilly and Co's expected revenue for the next quarter?
Eli Lilly and Co's expected revenue is 22.00B.
What is Eli Lilly and Co's price target?
Analysts forecast that Eli Lilly and Co's price target is USD 1.05K, with the highest forecast at USD 1.50K and the lowest forecast at USD 706.04.
How have Eli Lilly and CoLLY's recent earnings per share performed?
The market expectation was USD 7.95, while Eli Lilly and CoLLY's earnings per share (EPS) for the previous quarter was USD 8.27. EPS for the next quarter is expected at USD 9.58.
What is the analyst rating for Eli Lilly and Co?
Based on the ratings of Eli Lilly and Co's stock from 34 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.